CTRI/2021/01/030566
Not yet recruiting
未知
Measuring tumor-specific genetic alterations in cerebrospinal fluid (CSF) as a biomarker of tumor burden in malignant brain tumor patients. - Not applicable
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C719- Malignant neoplasm of brain, unspecified
- Sponsor
- Johns Hopkins University School of Medicine
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age \>18 years for Cohort 1: patients with suspected or confirmed malignant brain tumor who are eligible for surgical resection, chemotherapy or radiation treatments, as identified by the site PI or Co\-Is through routine clinical care processes
- •2\. Age \>12 years for Cohort 2: patients, including children, with malignant brain tumor, who are undergoing a diagnostic or therapeutic lumbar puncture, as identified by the site PI or Co\-Is through routine clinical care processes
- •3\. Life expectancy of greater than 6 months
- •4\. Patients must have normal lab criteria as defined below:
- •4a) Platelets \>\= 100,000/mcL
- •4b) PTT above institutional limits
- •4c) INR above institutional limits
- •5\) Ability to understand and the willingness to sign a written Informed Consent Form for patients \>18 years and an Assent form for patients \<18 years
- •6\) Both men and women of all races and ethnic groups are eligible for this study
Exclusion Criteria
- •1\) Patients who have an uncontrolled infection
- •2\) Patients who are receiving an investigational agent(s) that increases the risks associated with cerebrospinal fluid sampling
- •3\) Patients with clinical or radiographic evidence of elevated intracranial pressure (such as papilledema, obstructive hydrocephalus, or signs of herniation)
- •4\) Patients who are coagulopathic and are taking blood thinning products, such as plavix, lovenox, or coumadin. Patients maybe on steroids or anti\-convulsant therapy without affecting eligibility
- •5\) Women who are pregnant or suspect they are pregnant or lactating mothers
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Detection of tumor specific changes in nucleic acids in body fluids of patientswith malignanciesall types of tumorDRKS00009521niversitätsklinikum Freiburg1,000
Completed
Not Applicable
Identification of mutated and non-mutated tumor-associated antigens in glioblastomaglioblastomaglioblastoma multiforme10029211NL-OMON38803Academisch Medisch Centrum5
Completed
Not Applicable
Cancer related gene alteration analysis study in patients with endometrial cancerendometrial cancerJPRN-UMIN000027294SRL Medisearch Inc.200
Recruiting
Not Applicable
Identification of individual cancer mutations and analysis of their immunogenicitycancerC00-C97Malignant neoplasmsDRKS00011790BioNTech SE1,000
Not yet recruiting
Not Applicable
Genomic Study of Lung CancerCTRI/2019/01/017085TMAI PAI ENDOWMENT CHAIR